A Case of Refractory Non-Hodgkin's Lymphoma Which Had Responded to Continuous Infusion Therapy with Carboplatin and Etoposide

A 47 year- old female with non-Hodgkin's lymphoma (primary gastric With non-Hodgkin's cell type, stage IVb) was treated with continuous infusion therapy using Carboplatn (CBDCA) and Etoposide (VP-16) , after her disease had failed to respond to initial induction chemotherapies consisting of Cyclophospharnide, Doxorubicin, Etoposide, Ara-C, Pepleomycin, Vindesine and Methotrexate or aiso consisting of Doxorubicin, Vandesine and BHAC. No gastrointestinal symptoms nor renal toxicity appeared during continuous infusion therapy. Mild hepatic dysfunction was shown but temporal. In general , myelosuppression is often major dose-limiting factor, but it was mild and well tolerated in this therapy as compared wiith those of standard regimens. As anti-tumor effects, decreased lactate dehydrogenase (LDH) value and reduced tumor burden which was shown on abdominal computer tomograph or upper gastrointestinal barium radiography were observed. Ameliorated performance status was also seen after treatment. It is concluded that this chemotherapy regimen was worthy to be challenged for refractory cases which were not respondent to conventional chemotherapy schedules.

悪性リンパ腫

カルボプラチン(Carboplatin)

エトポシド(Etoposido)

化学療法